Targets › FABP
1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Nov 2028.
Open in Phaseline: the race on FABP, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Centre Hospitalier Universitaire de Besancon | MP0317 FAP-dependent CD40 agonist | FABP | Phase 2 | Advanced Biliary Tract Carcinoma | Nov 2028 |
Advanced Biliary Tract Carcinoma (1)
antibody (1)
Centre Hospitalier Universitaire de Besancon (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.